Objective: Hypoglycemia complicates intensive glycemia regimens in type 2 diabetes (T2D). Hyperglycemia induces macrophage priming and dysregulates T-cell activation/function. Immune cell response to acute hypoglycemia has not been investigated in T2D. Thus, immune mediators associated with macrophage/T-cell activation in response to insulin-induced hypoglycemia were studied.

Methods: Hypoglycaemia (<2.2mmol/l; <40mg/dl) was achieved in T2D (n=23) and controls (n=23) by intravenous insulin infusion. Somalogic analysis of plasma proteins related to macrophage/T-cell activation was performed at baseline, hypoglycemia and post-hypoglycemia to 24 hours.

Results: IL-4 and IL-13 (promotors of alternative macrophage activation (M2 macrophages)) decreased 2hours post-hypoglycemia in T2D (p<0.05). Co-stimulatory molecules of T-cell activation expressed in antigen presenting cells (APCs), CD80 and CD86, were decreased at 2h post-hypoglycemia (CD86 in T2D, p<0.05; CD80 in controls and T2D, p<0.05). Hypoglycemia did not affect ligands of co-stimulatory molecules, CTLA4 (ligand of CD80, expressed in APCs) and CD40LG (ligand of CD40, expressed in dendritic cells). The negative regulator of T-cell activation, IL-10, was decreased at 2h (p<0.001) and increased at 4h post-hypoglycemia (p<0.01). Elevation of CD80 (p<0.05) and CD86 (p<0.05), with increased T-cell proliferator IL-6 (p<0.05) was seen in T2D at 4h post-hypoglycemia. Positive correlations of IL10 with IL6, IL4, were observed at 2h post-hypoglycemia in T2D, suggesting a role for IL10 in altering immune cell activation mediators following hypoglycemia in T2D. No correlations with glucagon suggest changes are independent of glucose counter-regulation.

Conclusion: Induced hypoglycemia is associated with decreases in macrophage and T-cell activation mediators (cytokines) in T2D. Thus, this study reveals a novel link between hypoglycemia and inefficient immune system activation.

Disclosure

A.S.Moin: None. T.Sathyapalan: Other Relationship; Novo Nordisk, Abbott Diabetes, Research Support; Abbott Diabetes, Novo Nordisk, Eli Lilly and Company. S.Atkin: None. A.E.Butler: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.